Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era

Ryan S. Youland, Miran L. Blanchard, Roxana S Dronca, Lisa Kottschade, Svetomir Nenad Markovic, Kenneth R. Olivier, Sean S Park

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background To assess the role of radiotherapy in metastatic malignant melanoma (MM) patients in modern era. Materials and methods This is a retrospective study of MM patients treated with radiotherapy at Mayo Clinic from 1999 to 2014. Patients with pre- and post-treatment imaging studies (CT, MRI, and/or PET/CT) were assessed for metastasis failure (MF), regional/distant failure, and overall survival (OS). Results In 75 MM patients, 56 and 68 lesions were treated with conventional/hypofractionated radiotherapy (CHRT) and stereotactic body radiotherapy (SBRT), respectively. The median doses for CHRT and SBRT were 30 Gy and 50 Gy, respectively. 1-year MF was 17% (SBRT 6% vs CHRT 31%, p < 0.01). 1-year regional (5% vs 29%, p < 0.01) and distant progression (75% vs 89%, p < 0.01) were improved with SBRT. Median OS was 15.6 months (CHRT 7.0 vs SBRT 22.9, p < 0.01). Prognostic factors for OS included age ≤55 years (RR 0.25), oligometastatic disease (RR 0.34), SBRT (RR 0.38) and treating all lesions (RR 0.28, all p < 0.01). Conclusions SBRT for extracranial MM exhibited improved MF compared with CHRT, consistent with intracranial radiosurgery data. Though these data are retrospective and subject to selection bias, our findings support the prudent use of SBRT in a select group of favorable, oligometastatic MM patients, and should be discussed as an alternative to surgery and ablation.

Original languageEnglish (US)
Pages (from-to)25-30
Number of pages6
JournalClinical and Translational Radiation Oncology
Volume6
DOIs
StatePublished - Oct 1 2017

Fingerprint

Radiosurgery
Melanoma
Radiotherapy
Neoplasm Metastasis
Survival
Selection Bias
Retrospective Studies
Therapeutics

Keywords

  • Hypofractionation
  • Metastatic melanoma
  • Outcomes
  • Radiotherapy
  • SBRT

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. / Youland, Ryan S.; Blanchard, Miran L.; Dronca, Roxana S; Kottschade, Lisa; Markovic, Svetomir Nenad; Olivier, Kenneth R.; Park, Sean S.

In: Clinical and Translational Radiation Oncology, Vol. 6, 01.10.2017, p. 25-30.

Research output: Contribution to journalArticle

@article{e8253d05e3174cfa87ee610b09cb91a3,
title = "Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era",
abstract = "Background To assess the role of radiotherapy in metastatic malignant melanoma (MM) patients in modern era. Materials and methods This is a retrospective study of MM patients treated with radiotherapy at Mayo Clinic from 1999 to 2014. Patients with pre- and post-treatment imaging studies (CT, MRI, and/or PET/CT) were assessed for metastasis failure (MF), regional/distant failure, and overall survival (OS). Results In 75 MM patients, 56 and 68 lesions were treated with conventional/hypofractionated radiotherapy (CHRT) and stereotactic body radiotherapy (SBRT), respectively. The median doses for CHRT and SBRT were 30 Gy and 50 Gy, respectively. 1-year MF was 17{\%} (SBRT 6{\%} vs CHRT 31{\%}, p < 0.01). 1-year regional (5{\%} vs 29{\%}, p < 0.01) and distant progression (75{\%} vs 89{\%}, p < 0.01) were improved with SBRT. Median OS was 15.6 months (CHRT 7.0 vs SBRT 22.9, p < 0.01). Prognostic factors for OS included age ≤55 years (RR 0.25), oligometastatic disease (RR 0.34), SBRT (RR 0.38) and treating all lesions (RR 0.28, all p < 0.01). Conclusions SBRT for extracranial MM exhibited improved MF compared with CHRT, consistent with intracranial radiosurgery data. Though these data are retrospective and subject to selection bias, our findings support the prudent use of SBRT in a select group of favorable, oligometastatic MM patients, and should be discussed as an alternative to surgery and ablation.",
keywords = "Hypofractionation, Metastatic melanoma, Outcomes, Radiotherapy, SBRT",
author = "Youland, {Ryan S.} and Blanchard, {Miran L.} and Dronca, {Roxana S} and Lisa Kottschade and Markovic, {Svetomir Nenad} and Olivier, {Kenneth R.} and Park, {Sean S}",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.ctro.2017.09.002",
language = "English (US)",
volume = "6",
pages = "25--30",
journal = "Clinical and Translational Radiation Oncology",
issn = "2405-6308",

}

TY - JOUR

T1 - Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era

AU - Youland, Ryan S.

AU - Blanchard, Miran L.

AU - Dronca, Roxana S

AU - Kottschade, Lisa

AU - Markovic, Svetomir Nenad

AU - Olivier, Kenneth R.

AU - Park, Sean S

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background To assess the role of radiotherapy in metastatic malignant melanoma (MM) patients in modern era. Materials and methods This is a retrospective study of MM patients treated with radiotherapy at Mayo Clinic from 1999 to 2014. Patients with pre- and post-treatment imaging studies (CT, MRI, and/or PET/CT) were assessed for metastasis failure (MF), regional/distant failure, and overall survival (OS). Results In 75 MM patients, 56 and 68 lesions were treated with conventional/hypofractionated radiotherapy (CHRT) and stereotactic body radiotherapy (SBRT), respectively. The median doses for CHRT and SBRT were 30 Gy and 50 Gy, respectively. 1-year MF was 17% (SBRT 6% vs CHRT 31%, p < 0.01). 1-year regional (5% vs 29%, p < 0.01) and distant progression (75% vs 89%, p < 0.01) were improved with SBRT. Median OS was 15.6 months (CHRT 7.0 vs SBRT 22.9, p < 0.01). Prognostic factors for OS included age ≤55 years (RR 0.25), oligometastatic disease (RR 0.34), SBRT (RR 0.38) and treating all lesions (RR 0.28, all p < 0.01). Conclusions SBRT for extracranial MM exhibited improved MF compared with CHRT, consistent with intracranial radiosurgery data. Though these data are retrospective and subject to selection bias, our findings support the prudent use of SBRT in a select group of favorable, oligometastatic MM patients, and should be discussed as an alternative to surgery and ablation.

AB - Background To assess the role of radiotherapy in metastatic malignant melanoma (MM) patients in modern era. Materials and methods This is a retrospective study of MM patients treated with radiotherapy at Mayo Clinic from 1999 to 2014. Patients with pre- and post-treatment imaging studies (CT, MRI, and/or PET/CT) were assessed for metastasis failure (MF), regional/distant failure, and overall survival (OS). Results In 75 MM patients, 56 and 68 lesions were treated with conventional/hypofractionated radiotherapy (CHRT) and stereotactic body radiotherapy (SBRT), respectively. The median doses for CHRT and SBRT were 30 Gy and 50 Gy, respectively. 1-year MF was 17% (SBRT 6% vs CHRT 31%, p < 0.01). 1-year regional (5% vs 29%, p < 0.01) and distant progression (75% vs 89%, p < 0.01) were improved with SBRT. Median OS was 15.6 months (CHRT 7.0 vs SBRT 22.9, p < 0.01). Prognostic factors for OS included age ≤55 years (RR 0.25), oligometastatic disease (RR 0.34), SBRT (RR 0.38) and treating all lesions (RR 0.28, all p < 0.01). Conclusions SBRT for extracranial MM exhibited improved MF compared with CHRT, consistent with intracranial radiosurgery data. Though these data are retrospective and subject to selection bias, our findings support the prudent use of SBRT in a select group of favorable, oligometastatic MM patients, and should be discussed as an alternative to surgery and ablation.

KW - Hypofractionation

KW - Metastatic melanoma

KW - Outcomes

KW - Radiotherapy

KW - SBRT

UR - http://www.scopus.com/inward/record.url?scp=85069661985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069661985&partnerID=8YFLogxK

U2 - 10.1016/j.ctro.2017.09.002

DO - 10.1016/j.ctro.2017.09.002

M3 - Article

AN - SCOPUS:85069661985

VL - 6

SP - 25

EP - 30

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

SN - 2405-6308

ER -